For instance, KRAS is identified as the most frequently mutated oncogene in more than 90% of pancreatic cancer patients, and the constitutively active KRASG12D mutation has been proved to facilitate the formation of pancreatic intraepithelial neoplasia. Here, KRAS is linked to familial pancreatic carcinoma.